Briefing
Tirzepatide weight loss for MRD-positive early breast cancer
Phase 2 trial of tirzepatide in early breast cancer with molecular residual disease. Registry primary outcomes are ctDNA efficacy and distant disease-free survival. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting